Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)

In the register

The register attaches this trial to Ritlecitinib (Litfulo) (Pfizer), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.

What the registry records

Status

Available (expanded access)

Declared phase

No phase declared

Sponsor

Pfizer

Participants (registry)

—

Start

—

Primary completion

—

Study completion

—

Last registry update

November 2025

Countries

—

Full record on ClinicalTrials.gov ↗

Other trials of Ritlecitinib (Litfulo)

• NCT07821216Active, not recruiting

  Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data

• NCT07733765Phase 3Recruiting

  A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

• NCT07226531Completed

  Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US

• NCT07029828Phase 3Recruiting

  A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

• NCT07152119Recruiting

  A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.

• NCT07029711Phase 3Active, not recruiting

  A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

• NCT06873945Phase 3Recruiting

  A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

• NCT07200128Completed

  A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings

• NCT06531109Active, not recruiting

  Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

• NCT06279221Active, not recruiting

  Litfulo Capsules Special Investigation

• NCT05650333Phase 1Completed

  A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age

• NCT05549934Phase 2Completed

  Ritlecitinib for Cicatricial Alopecia